Clinical trial NCT02873819: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Squamous Cell Carcinoma of the Oral Cavity
Lead sponsor: Gliknik Inc.
Sponsor class: INDUSTRY
First posted: 2016-08-22
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.


Eligibility criteria: Inclusion Criteria:

1. Age \> 18 years
2. Histologic diagnosis of squamous cell carcinoma of the oral cavity including the lip, floor of mouth, anterior 2/3 of tongue, alveolus and gingiva, buccal mucosa, hard palate and retromolar trigone
3. Subjects must have undergone primary gross total resection (no re-resected patients are allowed) with fulfillment of at least 1 of the following histologic criteria for high-risk disease:

   * Histologic involvement of 2 or more regional lymph nodes
   * Any lymph node with histologic extracapsular extension (ECS)
   * Close (\<3mm) or positive surgical margins on microscopic evaluation with no gross residual tumor
4. No evidence of locoregional disease or distant metastases at screening. Subjects must have negative scans (CT, CT-PET or MRI) for locoregional recurrence, brain or lung metastases. A negative biopsy will be mandated in patients with a positive scan. Other evaluations should be performed as clinically indicated.
5. No history of distant metastases.
6. Tumor tissue from surgery or biopsy must be available to determine MAGE-A3 expression for correlative studies.
7. Following surgery, the patient must have received external beam radiotherapy (58-66 Gy in 2 Gy fractions, 5 days per week) with concomitant cisplatin starting within 8 weeks of surgery. A brief delay in the initiation of radiotherapy following 8 weeks post-surgery due to administrative reasons (e.g., start of RT on Mondays) may be permitted by the Medical Monitor. The cumulative dose of cisplatin the subject received must be \> 150 mg/m2. Protocol therapy must be initiated within a period of 4-8 weeks (28-56 days) following the end of RT.
8. The patient is, in the investigator's opinion, adequately recovered from the effects of surgery and chemoradiotherapy to participate in this study.
9. Blood HLA-A2 phenotype
10. ECOG Performance Status \< 1
11. Laboratory values obtained ≤ 14 days prior to randomization:

    * Absolute neutrophil count (ANC) ≥ 1500/μL (without intervention, e.g., G-CSF)
    * Platelets ≥ 75,000/μL (without intervention, e.g., transfusion)
    * Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥8.0 g/dl is acceptable).
    * Alkaline phosphatase ≤ 2.5 x upper limit of normal (ULN)
    * AST and ALT ≤ 2 x ULN
    * Creatinine \< 2 x ULN
    * Bilirubin \< 1.5x ULN (except for patients with Gilbert's disease, for whom the upper acceptable limit of serum bilirubin is 3mg/dL)
12. A female subject is eligible to enter the study if she is:

    * not pregnant or nursing; Female participants must not breastfeed during the study and for a period of 30 days following the last dose.
    * of non-childbearing potential (i.e., women who had a hysterectomy, are postmenopausal which is defined as 1 year without menses, have both ovaries surgically removed or have current documented tubal ligation); or
    * of childbearing potential (i.e., women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhea \[even severe\], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at screening, and agree to one of the following:

      * complete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent and 6 months after the last dose of study agent; or
      * consistent and correct use of 1 of the following highly effective methods of birth control for one month prior to the start of the study agent and 6 months after the last dose:
    * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    * progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    * intrauterine device (IUD)
    * intrauterine hormone-releasing system ( IUS)
    * bilateral tubal occlusion
    * vasectomized partner (if vasectomized is the sole sexual partner and has received medical confirmation of surgical success)
13. A male subject who is sexually active with a woman of childbearing potential is eligible to enter the study if he agrees to use effective contraception throughout the study and for 6 months after the last dose of study agent.
14. The subject must be capable of understanding the investigational nature, potential risks and benefits of the study and capable of providing valid informed consent. The subject must provide study specific informed consent prior to any protocol procedures that are not a part of standard care, including consent for assessment of HLA-A2 status, mandatory tissue submission for MAGE-A3 analysis and correlative studies.
15. The subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol.

Exclusion Criteria:

1. Known HIV or hepatitis B/C infection (testing not required). Subjects who are hepatitis C antibody positive may be enrolled if they are confirmed to have a negative viral load at screening.
2. Subjects with active autoimmune disease or a history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment.
3. Subjects who have used systemic corticosteroids or other immunosuppressants for any condition within 14 days of randomization. Inhaled or topical steroids are permitted.
4. Any medical condition which would, in the investigator's opinion, compromise the patient's ability to mount an immune response, renders the patient a poor candidate for this trial or could confound the results of the study
5. Major surgery or traumatic injury within 28 days of randomization
6. Prior splenectomy or organ allograft
7. Any other prior, concurrent or planned chemotherapy, immunotherapy, radiotherapy, device, or investigational therapy for this cancer other than those specified in this study.
8. History of other malignancy (i.e., excluding disease under study) within 3 years of randomization. Exceptions include: adequately-treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or adequately treated non-metastatic prostate cancer.
9. Known hypersensitivity to GM-CSF, yeast-derived products or any component of the GM-CSF drug product (e.g., mannitol) or poly-ICLC (e.g., carboxymethylcellulose).
10. Known hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.

Primary outcomes:
measure: Disease-free interval
timeFrame: Up to 2 years
Secondary outcomes:
measure: Disease-free survival (DFS)
timeFrame: up to 2 years
measure: Overall survival (OS)
timeFrame: up to 5 years
measure: Disease-free interval in a per protocol analysis
timeFrame: up to 2 years
measure: Adverse event profile
timeFrame: up to week 94
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: University of Maryland Greenebaum Cancer Center
state: Maryland
city: Budapest
country: Hungary
facility: National Institute of Oncology
city: Budapest
country: Hungary
facility: Semmelweis University
city: Debrecen
country: Hungary
facility: University of Debrecen Clinical Center
city: Kecskemét
country: Hungary
facility: Bacs-Kiskun County Teaching Hospital
city: Pecs
country: Hungary
facility: Medical Center of the University of Pecs
city: Bydgoszcz
country: Poland
facility: Oncology Center of Prof. Franciszek Lukaszczyk in Bydgoszcz
city: Kielce
country: Poland
facility: Swietokrzyskie Oncology Center in Kielce
city: Omsk
country: Russian Federation
facility: Clinical Oncology Center
city: Rostov-on-Don
country: Russian Federation
facility: Rostov Oncology Research Institute
city: Saint Petersburg
country: Russian Federation
facility: Leningrad Regional Oncology Center
city: Saint Petersburg
country: Russian Federation
facility: Oncology Center of Moskovskiy District
city: Saransk
country: Russian Federation
facility: Ogarev Mordovia State University
city: Sterlitamak
country: Russian Federation
facility: Clinical Hospital #1
city: Ufa
country: Russian Federation
facility: Republican Clinical Oncology Center
city: Yaroslavl
country: Russian Federation
facility: Regional Clinical Oncology Hospital
city: Belgrade
country: Serbia
facility: Institute of Oncology and Radiology of Serbia
city: Belgrade
country: Serbia
facility: Military Medical Academy, Clinic of Maxillofacial Surgery
city: Sremska Kamenica
country: Serbia
facility: Oncology Institute of Vojvodina (IOV), Clinic of Medical Oncology
city: Barcelona
country: Spain
facility: University Hospital Vall d'Hebron (HUVH)
city: Madrid
country: Spain
facility: University Hospital La Paz
city: Sabadell
country: Spain
facility: Parc Tauli Health Corporation
city: Cherkasy
country: Ukraine
facility: Cherkasy Regional Oncology Center
city: Chernihiv
country: Ukraine
facility: Chernihiv Regional Oncology Center
city: Dnipro
country: Ukraine
facility: Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital
city: Ivano-Frankivsk
country: Ukraine
facility: Ivano-Frankivsk Regional Oncology Center
city: Kharkiv
country: Ukraine
facility: Communal Non-profit enterprise "Regional Center of Oncology"
city: Kyiv
country: Ukraine
facility: Kyiv Regional Oncology Center
city: Lviv
country: Ukraine
facility: Lviv Regional Clinical Hospital
city: Odesa
country: Ukraine
facility: Odesa Regional Oncology Center
city: Poltava
country: Ukraine
facility: Poltava Regional Clinical Oncology Center
city: Sumy
country: Ukraine
facility: Sumy Regional Clinical Oncology Center
city: Vinnytsia
country: Ukraine
facility: Podillia Regional Oncology Center
Study officials:
References: